Rectal nitric oxide and fecal calprotectin in inflammatory bowel disease

References

• Gaya DR, Lyon TD, Duncan A, Neilly JB, Han S, Howell J, et al. Faecal calprotectin in the assessment of Crohn's disease activity. Q J Med 2005; 98: 435–41
   Google Scholar
• Tibble JA, Bjarnason I. Non-invasive investigation of inflammatory bowel disease. World J Gastroenterol 2001; 7: 460–5
   PubMed Web of Science ®Google Scholar
• Dijkstra G, van Goor H, Jansen PL, Moshage H. Targeting nitric oxide in the gastrointestinal tract. Curr Opin Invest Drugs 2004; 5: 529–36
   PubMedGoogle Scholar
• Herulf M, Ljung T, Hellstrom PM, Weitzberg E, Lundberg JON. Increased luminal nitric oxide in inflammatory bowel disease as shown with a novel minimally invasive method. Scand J Gastroenterol 1998; 3: 164–9
   Google Scholar
• Marletta MA, Spiering MM. Trace elements and nitric oxide function. J Nutr 2003; 133(Suppl 1)1431S–3
   PubMed Web of Science ®Google Scholar
• Beckman JS, Koppenol WH. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and the ugly. Am J Physiol 1996; 271: C1424–37
   PubMed Web of Science ®Google Scholar
• LJ Ignarro. Introduction and overview, in nitric oxide: a biology pathobiology. Los Angeles: Academic Press; 2000. pp 3–19.
   Google Scholar
• Lundberg JO, Hellstrom PM, Lundberg JM, Alving K. Greatly increased luminal nitric oxide in ulcerative colitis. Lancet 1994; 344: 1673–4
   PubMed Web of Science ®Google Scholar
• Reinders CL, Herulf M, Ljung T, Hollenberg J, Weitzberg E, Lundberg JO, et al. Rectal mucosal nitric oxide in differentiation of inflammatory bowel disease and irritable bowel syndrome. Clin Gastroenterol Hepatol 2005; 3: 777–83
   PubMed Web of Science ®Google Scholar
• Herulf M, Svenungsson B, Lagergren A, Ljung T, Morcos E, Wiklund NP, et al. Increased nitric oxide in infective gastroenteritis. J Infect Dis 1999; 180: 542–5
   PubMed Web of Science ®Google Scholar
• Herulf M, Blomquist L, Ljung T, Weitzberg E, Lundberg JO. Increased rectal nitric oxide in coeliac disease after local challenge with gluten. Scand J Gastroenterol 2001; 36: 169–73
   PubMed Web of Science ®Google Scholar
• Fagerhol MK, Dale I, Andersson T. A radioimmunoassay for a granulocyte protein as a marker in studies on the turnover of such cells. Bull Eur Physiopathol Respir 1980; 16 Suppl: 273–82
   PubMedGoogle Scholar
• Poullis A, Foster R, Shetty A, Fagerhol MK, Mendall MA. Bowel inflammation as measured by fecal calprotectin: a link between lifestyle factors and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 2004; 13: 279–84
   PubMed Web of Science ®Google Scholar
• Roseth AG, Fagerhol MK, Aadland E, Schjonsby H. Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. Scand J Gastroenterol 1992; 27: 793–8
   PubMed Web of Science ®Google Scholar
• Bunn SK, Bisset WM, Main MJ, Golden BE. Fecal calprotectin as a measure of disease activity in childhood inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2001; 32: 171–7
   PubMed Web of Science ®Google Scholar
• Fagerberg UL, Loof L, Merzoug RD, Hansson LO, Finkel Y. Fecal calprotectin levels in healthy children studied with an improved assay. J Pediatr Gastroenterol Nutr 2003; 37: 468–72
   PubMed Web of Science ®Google Scholar
• Roseth AG, Kristinsson J, Fagerhol MK, Schjonsby H, Aadland E, Nygaard K, et al. Faecal calprotectin: a novel test for the diagnosis of colorectal cancer?. Scand J Gastroenterol 1993; 28: 1073–6
   PubMed Web of Science ®Google Scholar
• Tibble JA, Sigthorsson G, Foster R, Scott D, Fagerhol MK, Roseth A, et al. High prevalence of NSAID enteropathy as shown by a simple faecal test. Gut 1999; 45: 362–6
   PubMed Web of Science ®Google Scholar
• Meling TR, Aabakken L, Roseth A, Osnes M. Faecal calprotectin shedding after short-term treatment with non-steroidal anti-inflammatory drugs. Scand J Gastroenterol 1996; 31: 339–44
   PubMed Web of Science ®Google Scholar
• Myren J, Bouchier IA, Watkinson G, Softley A, Clamp SE, de Dombal FT. The O.M.G.E. Multinational Inflammatory Bowel Disease Survey1976–1982. A further report on 2,657 cases. Scand J Gastroenterol 1984; Suppl 95: 1–27
   Google Scholar
• Lichtiger S, Present DH, Kornbluth A, Gelernt I, Bauer J, Galler G, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994; 330: 1841–5
   PubMed Web of Science ®Google Scholar
• Costa F, Mumolo MG, Bellini M, Romano MR, Ceccarelli L, Arpe P, et al. Role of faecal calprotectin as non-invasive marker of intestinal inflammation. Dig Liver Dis 2003; 35: 642–7
   PubMedGoogle Scholar
• Lundberg JO, Govoni M. Inorganic nitrate is a possible source for systemic generation of nitric oxide. Free Radic Biol Med 2004; 37: 395–400
   PubMed Web of Science ®Google Scholar
• Kolios G, Valatas V, Ward SG. Nitric oxide in inflammatory bowel disease: a universal messenger in an unsolved puzzle. Immunology 2004; 113: 427–37
   PubMed Web of Science ®Google Scholar
• Boughton-Smith NK, Evans SM, Hawkey CJ, Cole AT, Balsitis M, Whittle BJ, et al. Nitric oxide synthase activity in ulcerative colitis and Crohn's disease. Lancet 1993; 342: 338–40
   PubMed Web of Science ®Google Scholar
• Kolios G, Rooney N, Murphy CT, Robertson DA, Westwick J. Expression of inducible nitric oxide synthase activity in human colon epithelial cells: modulation by T lymphocyte derived cytokines. Gut 1998; 43: 56–63
   PubMed Web of Science ®Google Scholar
• Olesen M, Middelveld R, Bohr J, Tysk C, Lundberg JO, Eriksson S, et al. Luminal nitric oxide and epithelial expression of inducible and endothelial nitric oxide synthase in collagenous and lymphocytic colitis. Scand J Gastroenterol 2003; 38: 66–72
   PubMed Web of Science ®Google Scholar
• Reinders CI, Hellstrom PM, Bjork J, Weitzberg E, Lundberg JO. Effect of intravenous L-NMMA on nitric oxide production in collagenous colitis. Scand J Gastroenterol 2004; 39: 32–6
   PubMed Web of Science ®Google Scholar
• Lundberg JO, Herulf M, Olesen M, Bohr J, Tysk C, Wiklund NP, et al. Increased nitric oxide production in collagenous and lymphocytic colitis. Eur J Clin Invest 1997; 27: 869–71
   PubMed Web of Science ®Google Scholar
• Sobko T, Reinders CI, Jansson E, Norin E, Midtvedt T, Lundberg JO. Gastrointestinal bacteria generate nitric oxide from nitrate and nitrite. Nitric Oxide 2005; 13: 272–8
   PubMed Web of Science ®Google Scholar
• Roseth A. Determination of faecal calprotectin, a novel marker of organic gastrointestinal disorders. Dig Liver Dis 2003; 35: 607–9
   PubMedGoogle Scholar
• Isselbacher KJ. Calprotectin: a predictive marker of a relapse in ulcerative colitis. Postgrad Med 2005; 117: 8
   PubMed Web of Science ®Google Scholar
• Hanai H, Takeuchi K, Iida T, Kashiwagi N, Saniabadi AR, Matsushita I, et al. Relationship between fecal calprotectin, intestinal inflammation, and peripheral blood neutrophils in patients with active ulcerative colitis. Dig Dis Sci 2004; 49: 1438–43
   PubMed Web of Science ®Google Scholar
• Mendall MA, Patel P, Ballam L, Strachan D, Northfield TC. C-reactive protein and its relation to cardiovascular risk factors: a population-based cross-sectional study. Br Med J 1996; 312: 1061–5
   PubMed Web of Science ®Google Scholar
• Laforgia N, Baldassarre ME, Pontrelli G, Indrio F, Altomare MA, Di Bitonto G, et al. Calprotectin levels in meconium. Acta Paediatr 2003; 92: 463–6
   PubMed Web of Science ®Google Scholar